Biomarkers for Angiogenesis in Renal Cell Carcinoma and Neuro-endocrine Tumours.

Completed

• Conditions: Carcinoma; Neuroendocrine Tumors; Carcinoma, Renal Cell; Carcinoid Tumor; Pancreatic Islet Cell Tumors
• Interventions: Other: Blood sampling by vena punction.

• Registration Number: NCT01398306
• Lead Sponsor: University Medical Center Groningen

Brief Summary

The primary objective of this study is to analyse the concentration dopamine and serotonin in thrombocytes of patients with renal cell carcinoma and neuro-endocrine tumours compared to the concentrations of these catecholamines in healthy volunteers. The concentration dopamine and serotonin in thrombocytes with and without medication will also be evaluated.

Detailed Description

* To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours.

* To compare these concentrations with the concentrations catecholamines in thrombocytes of healthy controls.

* To analyse the concentration catecholamines in thrombocytes of patients with clear cell renal cell carcinoma and patients with low grade neuroendocrine tumours with and without medication.

Study Timeline

• Study Start: 2011-07
• Study First Submitted: 2011-07-19
• Study First Submitted QC: 2011-07-19
• Study First Posted: 2011-07-20
• Primary Completion: 2012-04
• Study Completion: 2012-04
• Status Verified: 2024-05
• Last Update Submitted: 2024-05-03
• Last Update Posted: 2024-05-06

Recruitment & Eligibility

• Status: COMPLETED
• Sex: All
• Target Recruitment: 40

Inclusion Criteria

• Age 18 years old or older.
• Patients with clear cell renal cell carcinoma with metastases or patients with a low-grade neuro-endocrine tumor with metastases.
• Written informed consent

Exclusion Criteria

• Use of L-dopa or SSRI.
• Patients with a second primary malignancy.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Arm && Interventions

Group	Intervention	Description
Group A	Blood sampling by vena punction.	Patients with clear cell renal cell carcinoma with metastases.
Group B	Blood sampling by vena punction.	Patients with low grade neuro-endocrine tumours with metastases.

Primary Outcome Measures

Name	Time	Method
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and healthy controls, and patients with low grade neuroendocrine tumours and healthy controls.	one year

Secondary Outcome Measures

Name	Time	Method
Difference in concentrations DA and 5-HT in thrombocytes of patients with clear cell renal cell carcinoma and low grade neuroendocrine tumours with and without medication.	one year

Trial Locations

Locations (1)

University Medical Center Groningen; 🇳🇱 Groningen, Netherlands